EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management

Orianne de la Brassinne Bonardeaux, Marie Moonen, Mai Linh Nguyen Trung, Helene Petitjean, Guy Jerusalem, Patrizio Lancellotti

Frontiers in Oncology · 29.07.2026 · 16

DOI: 10.3389/fonc.2026.1910598 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 29.07.2026. Verfasst von Orianne de la Brassinne Bonardeaux und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, GIGA Cardiovascular, University of Liège Hospital, Liège, Belgium. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myotoxicity, defined as immune-mediated injury to cardiac and/or skeletal muscle, has emerged as one of the most severe and lethal immune-related adverse events (irAE) in patients receiving immune checkpoint inhibitors (ICIs). Although myocarditis in oncology is not restricted to ICIs and may also occur after traditional cytotoxic chemotherapy, radiotherapy, or selected targeted therapies, ICI-associated cardiomyotoxicity is distinguished by its early onset, frequent overlap with myositis, and myasthenia gravis, and high case-fatality rate. This review outlines myotoxicity within the broader context of cancer therapy-related cardiovascular toxicity, then focuses on the distinct syndromes associated with different immunotherapy classes. For ICIs, we detail a spectrum including myocarditis, myositis, and overlap syndromes, quantified by data from large registries. For Chimeric Antigen Receptor (CAR) T-cell therapy, we focus on cardiotoxicity in the context of cytokine release syndrome (CRS). Diagnostic sections discuss clinical presentation, biomarkers, and imaging, emphasizing the need for troponin I over T and the nuanced interpretation of cardiac magnetic resonance (CMR). The POWER risk score is presented as the first externally validated tool to predict early major adverse cardiomyotoxic events (MACE) from ICIs. Finally, the review proposes distinct management strategies for ICI- versus CAR-T-related toxicity and outlines pragmatic surveillance protocols.

Schlagwörter

Stichwörter der Autor:innen

CAR T-cell therapycardio-oncologyimmune checkpoint inhibitorsimmune-related adverse events (IRAE)myotoxicity

Autor:innen und Institutionen

  • Department of Cardiology, GIGA Cardiovascular, University of Liège Hospital, Liège, Belgium.
  • Department of Oncology, University of Liège Hospital, Liège, Belgium.

Zitieren

APA

de la Brassinne Bonardeaux, O., Moonen, M., Nguyen Trung, M. L., Petitjean, H., Jerusalem, G., & Lancellotti, P. (2026). Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1910598

Vancouver

de la Brassinne Bonardeaux O, Moonen M, Nguyen Trung ML, Petitjean H, Jerusalem G, Lancellotti P. Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1910598

BibTeX
@article{delaBrassinneBonardeaux2026,
  author = {de la Brassinne Bonardeaux, Orianne and Moonen, Marie and Nguyen Trung, Mai Linh and Petitjean, Helene and Jerusalem, Guy and Lancellotti, Patrizio},
  title = {Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1910598}
}
Kostenlos starten →